Ascendis Pharma announced that the European Medicines Agency's CHMP has issued a positive opinion recommending approval of TransCon CNP (navepegritide), a once-weekly treatment for achondroplasia in children aged two and older with open growth plates. This follows clinical data from three randomized trials and up to three years of extension studies. The final decision by the European Commission is expected in Q4 2026, with planned EU launch under the brand YUVIWEL in Germany in early 2027. This treatment offers continuous exposure to active CNP, addressing the underlying genetic signaling imbalance in achondroplasia, a rare genetic disorder affecting bone growth and causing serious complications.
Ascendis Pharma (ASND) shares trade at USD 225.25 on Pluang as of Oct 17, 2026 21:11 WIB, down 0.60% for the day. The stock's market cap stands at $14.81 billion with a 52-week high of $277.18. This trading activity occurs alongside the CHMP's positive opinion on TransCon CNP for achondroplasia, highlighting investor focus on the company's pipeline developments.
Ascendis Pharma announced that the European Medicines Agency's CHMP has given a positive opinion for TransCon CNP (Navepegritid), a once-weekly treatment for achondroplasia in children aged 2 and above with open growth plates. This recommendation sup...
The European Medicines Agency's CHMP has recommended marketing authorization for Ascendis Pharma's once-weekly TransCon CNP (navepegritide) to treat achondroplasia in children aged two and older with open growth plates. This positive opinion follows ...
